Accessibility Menu
VitaSpring Biomedical logo

VitaSpring Biomedical(OTC) VSBC

Market Cap$2.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-97%
5 Year-100%
1 Year-99%
1 Month+0%
$0.01
+0.00%
+0.00Today
VitaSpring Biomedical last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-06
VitaSpring Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-02-12
1 month+0%USD 0.012026-02-12
3 month+0%USD 0.012026-02-12
Year to date-98.89%USD 1.002025-11-03
1 year-98.89%USD 1.002025-03-05
3 year-99.93%USD 16.002023-06-15
5 year-99.93%USD 15.802021-07-07
Since inception-97.36%USD 0.422019-11-13

VitaSpring Biomedical Financials at a Glance

Market Cap

$2.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$410.67K

EPS (TTM)

-$0.00

P/E Ratio

-5.55

Dividend

$0.00

Beta (Volatility)

4.63 (High)

Price

$0.01

Volume

35

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $1.00

Estimated Earnings Date

N/A

VSBC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About VitaSpring Biomedical

VitaSpring develops cell-based medicines for health, beauty, and anti-aging needs. Its products aim to help clinics and wellness providers offer regenerative therapies. The company currently has no active sales or marketed products.

What’s in the VitaSpring Toolbox?

  • Stem cell products: Sourced from related-party vendors, intended for regenerative medicine and wellness clinics (100% of historical revenue).
  • Exosome products: Cell-derived particles, aimed at beauty and anti-aging applications (100% of historical revenue).
  • Resale model: No in-house manufacturing; products sourced and resold to clients.
  • Single business line: All revenue from cell-based product sales; no diversification reported.
  • No active offerings: No current product sales, research, or clinical trials as of April 2024.

Growth Spurts and Growing Pains

  • Changed name from Shemn Corp. to VitaSpring in February 2020.
  • Suspended commercial operations in 2023 to restructure business model.
  • No acquisitions, partnerships, or global expansions reported since 2019 IPO.
  • Focused on evaluating future strategies and regulatory positioning in 2024.

Why VitaSpring Is a Bit Different

The company targets regenerative medicine by reselling stem cell and exosome products. It has no proprietary brands or manufacturing, relying on related-party suppliers. Operations are currently paused, with no active distribution or research underway.

Five Things You Need to Know

  • Revenue was $0 in QQ3 2023, down 100% from $200,400 in QQ3 2022.
  • Net loss was $-182,942 in QQ3 2023, a 33.9% increase from prior year.
  • Cash flow improved to $2,460 in QQ3 2023, up 100.6% from negative $378,882 in QQ3 2022.
  • Working capital deficit was $3.59 million as of April 30, 2024.

Bottom Line

VitaSpring has shifted from active sales to business restructuring and strategy review. The company faces significant operational and financial challenges, with no current product revenue or development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Ssu-Chuan Lai, PhD

Website

www.vitaspringbio.com

Headquarters

Riverside, CA 92507, US

VSBC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

9.39%

Return on Capital

N/A

Return on Assets

-3592.29%

Earnings Yield

-18.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

207.03M

Volume

35

Avg. Volume

0.556

Financials (TTM)

Gross Profit

-$2.49K

Operating Income

-$392.11K

EBITDA

-$389.62K

Operating Cash Flow

$4.18K

Capital Expenditure

$0.00

Free Cash Flow

$4.18K

Cash & ST Invst.

$8.17K

Total Debt

$0.00

VitaSpring Biomedical Performance Analysis

VitaSpring Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-01-31USD 0N/A
20242024-01-31USD 0N/A
20252025-01-31USD 0N/A
20262026-01-31USD 0N/A
VitaSpring Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-31N/A
Q32025-10-31N/A
Q42026-01-31N/A
Q12026-04-30N/A
VitaSpring Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-01-31USD -0.02N/A
20242024-01-31USD -0.01-73.3%
20252025-01-31USD -0.00-31.5%
20262026-01-31USD -0.00-45.9%
VitaSpring Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-31N/A
Q32025-10-31-40.0%
Q42026-01-3142.9%
Q12026-04-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.49K

+33.9%

Gross Margin

0.00%

N/A

Market Cap

$2.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.30M

N/A

Employees

1

N/A

Net Income

-$75.84K

+45.0%

EBITDA

-$73.36K

+59.1%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$8.17K

-66.0%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-35.92%

N/A

Return on Invested Capital

8.70%

N/A

Free Cash Flow

$6.08K

+147.3%

Operating Cash Flow

$6.08K

+147.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IUGNFImugene Limited
$0.07-9.12%
AURXNuo Therapeutics, Inc.
$1.00+0.00%
SPHRYStarpharma Holdings Limited
$5.26+6.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.21+0.06%
SPCXSpace Exploration Technologies
$131.46-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.73-0.05%

Questions About VSBC

What is the current price of VitaSpring Biomedical?

VitaSpring Biomedical is trading at $0.01 per share.

What is the 52-week range for VitaSpring Biomedical?

Over the past 52 weeks, VitaSpring Biomedical has traded between $0.01 and $1.00.

How much debt does VitaSpring Biomedical have?

As of the most recent reporting period, VitaSpring Biomedical reported total debt of $0.00.

How much cash does VitaSpring Biomedical have on hand?

VitaSpring Biomedical reported $8.17K in cash and cash equivalents in its most recent financial results.

What is VitaSpring Biomedical’s dividend yield?

VitaSpring Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services